Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides, a joint venture between Akorn and Strides Arcolab, has received the FDA's approval for an abbreviated new drug application for pamidronate disodium injection, 3mg/mL and 9mg/mL in 10mL vials.
Subscribe to our email newsletter
Pamidronate disodium injection is indicated for the treatment of hypercalcemia associated with malignancy and Paget’s disease.
Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “We are pleased to announce the abbreviated new drug application approval for pamidronate disodium injection.”